Home Tags Stemcentrx

Tag: Stemcentrx

AbbVie Discontinues Research and Development Program for Rovalpituzumab Tesirine

MERU, a Phase III trial evaluating rovalpituzumab tesirine (Rova-T / SC16LD6.5; AbbVie) as a first-line maintenance therapy for advanced small-cell lung cancer (SCLC), demonstrated...
Featured Image: General views at the American Society for Clinical Oncology (ASCO) annual meeting. Courtesy: © ASCO/Max Gersh 2015. Used with permission.

AbbVie Demonstrates Progress in Oncology Research at ASCO 2016

Chemotherapy remains the standard of care in the treatment of many types of cancer. However, one of the problems with chemotherapeutics is that it...

Expanding Oncology Presence: AbbVie Acquires Stemcentrx

AbbVie, a global biopharmaceutical company has agreed to acquire Stemcentrx and its lead late-stage asset rovalpituzumab tesirine (Rova-T), also known as SC16LD6.5, which is currently...